Market Movers (8-K)
See all →Filana Therapeutics reported Q2 2026 financial results, showing reduced operating expenses and net loss, while continuing to address an FDA clinical hold on its TSC-related epilepsy therapy.
Delay expected
Filana Therapeutics, Inc. announced amendments to its 2018 Omnibus Incentive Plan, approved by stockholders at the 2026 Annual Meeting, increasing authorized shares and extending the plan's term.
Filana Therapeutics reported Q1 2026 financial results, highlighting a reduced net loss and cash burn, while advancing its simufilam program for TSC-related epilepsy.
Delay expected
Michael ODonnell will resign from the Filana Therapeutics Board of Directors at the company's 2026 annual meeting.
Filana Therapeutics reported a significant net loss increase in 2025, driven by a non-recurring gain in the prior year, while actively addressing an FDA clinical hold on its TSC-related epilepsy program.
Worse than expected
Delay expected
Cassava Sciences announced the closure of the U.S. Department of Justice's inquiry into research misconduct allegations, ending all federal investigations.
Better than expected
Quarterly Earnings (10-Q)
See all →Filana Therapeutics reports significant progress in resolving legal matters and a clinical hold on its simufilam IND, while R&D expenses decrease due to program shifts.
Delay expected
Capital raise
Filana Therapeutics reports a net loss of $10.3 million for Q1 2026 as it pivots focus to TSC-related epilepsy research.
Delay expected
Capital raise
Cassava Sciences reported a net loss of $10.8 million for Q3 2025, discontinuing its Alzheimer's program to focus on TSC-related epilepsy with a new Yale license.
Capital raise
Worse than expected
Cassava Sciences reports significant losses and discontinues its Alzheimer's drug program, pivoting to a new epilepsy indication while facing substantial legal costs.
Capital raise
Worse than expected
Cassava Sciences is pivoting its focus to Tuberous Sclerosis Complex (TSC) after Phase 3 trials for its Alzheimer's drug, simufilam, failed to meet endpoints, leading to the discontinuation of its Alzheimer's program.
Worse than expected
10-Q: Cassava Sciences Reports Third Quarter 2024 Financial Results and Provides Clinical Program Updates
Cassava Sciences' Phase 3 Alzheimer's drug Simufilam shows promise in trials, with top-line results for the 52-week study expected by the end of 2024, despite ongoing legal challenges and leadership changes.
Worse than expected
Capital raise
Annual Reports (10-K)
Filana Therapeutics, formerly Cassava Sciences, has discontinued its Alzheimer's program, pivoted to TSC-related epilepsy, and faces a clinical hold on its lead candidate, simufilam, while settling significant legal claims.
Delay expected
Worse than expected
Capital raise
Cassava Sciences reports discontinuation of Alzheimer's clinical trials, a settlement with the SEC, and a strategic shift towards Tuberous Sclerosis Complex (TSC)-related epilepsy in its 2024 10-K filing.
Worse than expected
Cassava Sciences outlines its common stock and warrant details, including authorized shares, voting rights, and warrant exercise conditions, in its annual 10-K filing.
Capital raise
Insider Trading (Form 4)
See all →A director at Cassava Sciences Inc. acquired 8,600 shares of common stock at $2.90 per share, signaling confidence.
Better than expected
Cassava Sciences' President and CEO, Richard Barry, reported a transaction involving the purchase of 150,000 shares of common stock at an average price of $2.76, though the reported transaction date is in the future.
Cassava Sciences' President and CEO, Richard Barry, plans to purchase 73,385 shares of common stock at an average price of $2.75 per share on November 19, 2025.
Cassava Sciences Inc. Director Dawn Carter Bir was granted 53,000 stock options with an exercise price of $3.98, vesting over three years.
Cassava Sciences' Chief Operating & Legal Officer, Robert Christopher Cook, acquired 13,725 shares of common stock at $2.91 per share.
Cassava Sciences President and CEO, Richard Barry, acquired 7,172 shares of common stock through a trust at an average price of $2.28 per share.
Proxy Statements (Def-14A)
Cassava Sciences seeks shareholder approval for increased director compensation and a reduction in board classification from three to two classes at its upcoming annual meeting.
Cassava Sciences will hold its 2024 Annual Meeting of Stockholders virtually on May 9, 2024, to vote on director elections, auditor ratification, and executive compensation.
Schedule 13G - Passive Investments
The Vanguard Group has updated its beneficial ownership in Cassava Sciences Inc., reporting a 4.49% stake as of June 30, 2025, falling below the 5% Schedule 13G reporting threshold.
BlackRock, Inc. has filed an amendment to its Schedule 13G, disclosing a 3.2% passive beneficial ownership stake in Cassava Sciences Inc. as of June 30, 2025.